1
|
Hausenloy DJ, Lim MX, Chan MHH, Paradies V, Francis R, Kotecha T, Knight DS, Fontana M, Kellman P, Moon JC, Bulluck H. Interrogation of the infarcted and salvaged myocardium using multi-parametric mapping cardiovascular magnetic resonance in reperfused ST-segment elevation myocardial infarction patients. Sci Rep 2019; 9:9056. [PMID: 31227761 PMCID: PMC6588689 DOI: 10.1038/s41598-019-45449-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2018] [Accepted: 06/03/2019] [Indexed: 01/06/2023] Open
Abstract
We used multi-parametric cardiovascular magnetic resonance (CMR) mapping to interrogate the myocardium following ST-segment elevation myocardial infarction (STEMI). Forty-eight STEMI patients underwent CMR at 4 ± 2 days. One matching short-axis slice of native T1 map, T2 map, late gadolinium enhancement (LGE), and automated extracellular volume fraction (ECV) maps per patient were analyzed. Manual regions-of-interest were drawn within the infarcted, the salvaged and the remote myocardium. A subgroup analysis was performed in those without MVO and with ≤75% transmural extent of infarct. For the whole cohort, T1, T2 and ECV in both the infarcted and the salvaged myocardium were significantly higher than in the remote myocardium. T1 and T2 could not differentiate between the salvaged and the infarcted myocardium, but ECV was significantly higher in the latter. In the subgroup analysis of 15 patients, similar findings were observed for T1 and T2. However, there was only a trend towards ECVsalvage being higher than ECVremote. In the clinical setting, current native T1 and T2 methods with the specific voxel sizes at 1.5 T could not differentiate between the infarcted and salvaged myocardium, whereas ECV could differentiate between the two. ECV was also higher in the salvaged myocardium when compared to the remote myocardium.
Collapse
Affiliation(s)
- Derek J Hausenloy
- The Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London, London, United Kingdom.,The National Institute of Health Research University College London Hospitals Biomedical Research Centre, London, United Kingdom.,Tecnologico de Monterrey, Centro de Biotecnologia-FEMSA, Nuevo Leon, Mexico.,National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore.,Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, Singapore, Singapore.,Yong Loo Lin School of Medicine, National University Singapore, Singapore, Singapore
| | - Mei Xing Lim
- National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore.,Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, Singapore, Singapore
| | - Mervyn H H Chan
- National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore.,Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, Singapore, Singapore
| | - Valeria Paradies
- National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore
| | - Rohin Francis
- The Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London, London, United Kingdom.,National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom
| | - Tushar Kotecha
- National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom
| | - Daniel S Knight
- National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom
| | - Marianna Fontana
- National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom
| | - Peter Kellman
- National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, USA
| | - James C Moon
- The National Institute of Health Research University College London Hospitals Biomedical Research Centre, London, United Kingdom.,Tecnologico de Monterrey, Centro de Biotecnologia-FEMSA, Nuevo Leon, Mexico
| | - Heerajnarain Bulluck
- The Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London, London, United Kingdom. .,Golden Jubilee National Hospital, Clydebank, Glasgow, United Kingdom.
| |
Collapse
|
2
|
Bulluck H, Chowdhury N, Lim MX, Allen JC, Bryant JA, Chan MY, Chan MHH, Chin CWL, Ho HH, Lim ST, Tan RS, Tan JW, Wong PE, Yeo KK, Cook SA, Hausenloy DJ. Feasibility to Perform T 2 * Mapping Postcontrast Administration in Reperfused STEMI Patients for the Detection of Intramyocardial Hemorrhage. J Magn Reson Imaging 2019; 51:644-645. [PMID: 31087614 DOI: 10.1002/jmri.26779] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2019] [Revised: 04/22/2019] [Accepted: 04/22/2019] [Indexed: 11/12/2022] Open
Affiliation(s)
- Heerajnarain Bulluck
- Department of Cardiology, National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore.,Department of Cardiology, Norfolk and Norwich University Hospital, Norwich, UK
| | - Nazia Chowdhury
- Department of Cardiology, National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore.,Cardiovascular and Metabolic Disorders Program, Duke-National University Singapore Medical School, Singapore, Singapore
| | - Mei Xing Lim
- Department of Cardiology, National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore.,Cardiovascular and Metabolic Disorders Program, Duke-National University Singapore Medical School, Singapore, Singapore
| | - John C Allen
- Centre for Quantitative Medicine, Office of Clinical Sciences, Duke-National University of Singapore, Singapore
| | - Jennifer A Bryant
- Department of Cardiology, National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore
| | - Mark Y Chan
- Department of Cardiology, National University Heart Centre, Singapore, Singapore
| | - Mervyn H H Chan
- Department of Cardiology, National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore.,Cardiovascular and Metabolic Disorders Program, Duke-National University Singapore Medical School, Singapore, Singapore
| | - Calvin W L Chin
- Department of Cardiology, National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore
| | - Hee Hwa Ho
- Department of Cardiology, Tan Tock Seng Hospital, Singapore, Singapore
| | - Soo T Lim
- Department of Cardiology, National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore
| | - Ru-San Tan
- Department of Cardiology, National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore
| | - Jack W Tan
- Department of Cardiology, National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore
| | - Philip E Wong
- Department of Cardiology, National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore
| | - Khung K Yeo
- Department of Cardiology, National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore
| | - Stuart A Cook
- Department of Cardiology, National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore
| | - Derek J Hausenloy
- Department of Cardiology, National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore.,Cardiovascular and Metabolic Disorders Program, Duke-National University Singapore Medical School, Singapore, Singapore.,The Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London, UK.,The National Institute of Health Research University College London Hospitals Biomedical Research Centre, London, UK.,Tecnologico de Monterrey, Centro de Biotecnologia-FEMSA, Nuevo Leon, Mexico.,Yong Loo Lin School of Medicine, National University Singapore, Singapore, Singapore
| |
Collapse
|
3
|
Bulluck H, Chan MHH, Bryant JA, Chai P, Chawla A, Chua TS, Chung YC, Fei G, Ho HH, Ho AFW, Hoe AJ, Imran SS, Lee CH, Lim SH, Liew BW, Yun PLZ, Hock MOE, Paradies V, Roe MT, Teo L, Wong AS, Wong E, Wong PE, Watson T, Chan MY, Tan JW, Hausenloy DJ. Platelet inhibition to target reperfusion injury trial: Rationale and study design. Clin Cardiol 2018; 42:5-12. [PMID: 30421441 DOI: 10.1002/clc.23110] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/27/2018] [Revised: 11/07/2018] [Accepted: 11/08/2018] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND In ST-segment elevation myocardial infarction (STEMI) patients treated with primary percutaneous coronary intervention (PPCI), current oral P2Y12 platelet inhibitors do not provide maximal platelet inhibition at the time of reperfusion. Furthermore, administration of cangrelor prior to reperfusion has been shown in pre-clinical studies to reduce myocardial infarct (MI) size. Therefore, we hypothesize that cangrelor administered prior to reperfusion in STEMI patients will reduce the incidence of microvascular obstruction (MVO) and limit MI size in STEMI patients treated with PPCI. METHODS The platelet inhibition to target reperfusion injury (PITRI) trial, is a phase 2A, multi-center, double-blinded, randomized controlled trial, in which 210 STEMI patients will be randomized to receive either an intravenous (IV) bolus of cangrelor (30 μg/kg) followed by a 120-minute infusion (4 μg/kg/min) or matching saline placebo, initiated prior to reperfusion (NCT03102723). RESULTS The study started in October 2017 and the anticipated end date would be July 2020. The primary end-point will be MI size quantified by cardiovascular magnetic resonance (CMR) on day 3 post-PPCI. Secondary endpoints will include markers of reperfusion, incidence of MVO, MI size, and adverse left ventricular remodeling at 6 months, and major adverse cardiac and cerebrovascular events. SUMMARY The aim of the PITRI trial is to assess whether cangrelor administered prior to reperfusion would reduce acute MI size and MVO, as assessed by CMR.
Collapse
Affiliation(s)
- Heerajnarain Bulluck
- The Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London, London, UK.,Department of Cardiology, Norfolk and Norwich University Hospital, Norwich, UK.,Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore
| | - Mervyn H H Chan
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, Singapore, Singapore
| | - Jennifer A Bryant
- Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore
| | - Ping Chai
- Department of Cardiology, National University Heart Centre, Singapore, Singapore
| | - Ashish Chawla
- Department of Cardiology, Khoo Teck Puat Hospital, Singapore, Singapore
| | - Terrance S Chua
- Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore
| | | | - Gao Fei
- Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore
| | - Hee H Ho
- Department of Cardiology, Tan Tock Seng Hospital, Singapore, Singapore
| | - Andrew F W Ho
- SingHealth Emergency Medicine Residency Programme, Singapore, Singapore.,SingHealth Duke-NUS Emergency Medicine Academic Clinical Programme, Singapore, Singapore
| | - Andrew J Hoe
- Department of Cardiology, Mount Elizabeth Hospital, Novena, Singapore
| | - Syed S Imran
- Department of Cardiology, Khoo Teck Puat Hospital, Singapore, Singapore
| | - Chi-Hang Lee
- Department of Cardiology, National University Heart Centre, Singapore, Singapore
| | - Swee H Lim
- Department of Emergency Medicine, Singapore General Hospital, Singapore, Singapore
| | - Boon W Liew
- Department of Cardiology, Changi General Hospital, Singapore, Singapore
| | - Patrick L Z Yun
- Department of Cardiology, Khoo Teck Puat Hospital, Singapore, Singapore
| | - Marcus O E Hock
- Department of Emergency Medicine, Singapore General Hospital, Singapore, Singapore.,Health Services and Systems Research, Duke-NUS Medical School, Singapore, Singapore
| | - Valeria Paradies
- Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore
| | - Matthew T Roe
- Duke Clinical Research Institute, Duke University, Durham, North Carolina
| | - Lynette Teo
- Department of Diagnostic Imaging, National University Hospital, Singapore, Singapore
| | - Aaron S Wong
- Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore
| | - Evelyn Wong
- Department of Emergency Medicine, Singapore General Hospital, Singapore, Singapore
| | - Philip E Wong
- Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore
| | - Timothy Watson
- Department of Cardiology, Mount Elizabeth Hospital, Novena, Singapore
| | - Mark Y Chan
- Department of Cardiology, National University Heart Centre, Singapore, Singapore
| | - Jack W Tan
- Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore
| | - Derek J Hausenloy
- The Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London, London, UK.,Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore.,Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, Singapore, Singapore.,Tecnologico de Monterrey, Escuela de Ingenieria y Ciencias, Centro de Biotecnologia-FEMSA, Nuevo Leon, México.,The National Institute of Health Research University College London Hospitals Biomedical Research Centre, London, UK.,Yong Loo Lin School of Medicine, National University Singapore, Singapore, Singapore
| |
Collapse
|
4
|
Bulluck H, Chan MHH, Paradies V, Yellon RL, Ho HH, Chan MY, Chin CWL, Tan JW, Hausenloy DJ. Incidence and predictors of left ventricular thrombus by cardiovascular magnetic resonance in acute ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: a meta-analysis. J Cardiovasc Magn Reson 2018; 20:72. [PMID: 30404623 PMCID: PMC6222991 DOI: 10.1186/s12968-018-0494-3] [Citation(s) in RCA: 66] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2018] [Accepted: 10/09/2018] [Indexed: 12/04/2022] Open
Abstract
INTRODUCTION The incidence of left ventricular (LV) thrombus formation in ST-segment elevation myocardial infarction (STEMI) patients in the current era of primary percutaneous coronary intervention (PCI) is not well established. We performed a meta-analysis to assess the actual incidence and predictors of LV thrombus by cardiovascular magnetic resonance (CMR) in STEMI treated by primary PCI. METHODS We searched MEDLINE and EMBASE databases up to February 2018. We included all studies published as a full-text article, reporting the incidence of LV thrombus by CMR within 1 month following acute STEMI in patients treated by primary PCI. A binary random-effects model was used to estimate the pooled incidence of LV thrombus. The diagnostic performance of transthoracic echocardiography (TTE) as compared with CMR was pooled to obtain the sensitivity and specificity of TTE with CMR as the gold standard. Embolic and bleeding complications of LV thrombus were also evaluated. RESULTS Ten studies were included in the meta-analysis. The incidence of LV thrombus by CMR in all-comer STEMI patients (n = 2072) was 6.3% with 96% of LV thrombus occurring in those with anterior STEMI (12.2% incidence). When only anterior STEMI with LVEF< 50% were considered (n = 447), the incidence of LV thrombus was 19.2%. Compared with CMR, the sensitivity of TTE to detect LV thrombus was 29% with a specificity of 98%. The sensitivity of TTE increased to 70% in those with anterior STEMI and reduced LVEF. LV thrombus resolved in 88% of cases by 3 to 6 months. After 1-2 years follow-up, the embolic complication rate was similar at 1.5% (P = 0.25) but the bleeding complication rate was significantly higher (8.8% versus 0.5%, P < 0.001) in the LV thrombus group on triple therapy when compared to the no LV thrombus group on dual antiplatelet therapy. CONCLUSION In the primary PCI era, CMR detection of an LV thrombus post-STEMI remains high with incidence of nearly 20% in anterior STEMI with depressed LVEF. Patients with LV thrombus treated by triple therapy had similar embolic complications but higher bleeding complications than those with no LV thrombus treated with dual antiplatelet therapy. A 3 month follow-up CMR scan to guide anticoagulation duration might help mitigate bleeding risk.
Collapse
Affiliation(s)
- Heerajnarain Bulluck
- Norfolk and Norwich University Hospital, Colney Lane, Norwich, NR4 7UY UK
- The Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London, London, UK
| | - Mervyn H. H. Chan
- National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore
- National Heart Centre Singapore, Singapore, Singapore
| | - Valeria Paradies
- National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore
| | - Robert L. Yellon
- The Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London, London, UK
| | - He H. Ho
- Department of Cardiology, Tan Tock Seng Hospital, Singapore, Singapore
| | - Mark Y. Chan
- Department of Cardiology, National University Hospital, Singapore, Singapore
| | | | - Jack W. Tan
- National Heart Centre Singapore, Singapore, Singapore
| | - Derek J. Hausenloy
- The Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London, London, UK
- National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore
- Barts Heart Centre, St Bartholomew’s Hospital, London, UK
- The National Institute of Health Research University College London Hospitals Biomedical Research Centre, London, UK
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, Singapore, Singapore
- Yong Loo Lin School of Medicine, National University Singapore, Singapore, Singapore
| |
Collapse
|